News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
263,596 Results
Type
Article (14061)
Company Profile (282)
Press Release (249253)
Section
Business (79430)
Career Advice (152)
Deals (13215)
Drug Delivery (34)
Drug Development (50381)
Employer Resources (31)
FDA (5699)
Job Trends (5120)
News (144250)
Policy (10023)
Tag
Academia (901)
Alliances (21591)
Alzheimer's disease (784)
Antibody-drug conjugate (ADC) (70)
Approvals (5686)
Artificial intelligence (90)
Bankruptcy (100)
Best Places to Work (4553)
Biotechnology (232)
Breast cancer (124)
Cancer (1049)
Cardiovascular disease (85)
Career advice (132)
CAR-T (86)
Cell therapy (250)
Clinical research (40441)
Collaboration (407)
Compensation (166)
COVID-19 (1020)
C-suite (104)
Cystic fibrosis (73)
Data (1076)
Diabetes (98)
Diagnostics (1248)
Drug discovery (65)
Earnings (29090)
Events (47512)
Executive appointments (330)
FDA (6153)
Funding (388)
Gene editing (73)
Gene therapy (188)
GLP-1 (336)
Government (1070)
Healthcare (6561)
Infectious disease (1066)
Inflammatory bowel disease (100)
IPO (7235)
Job creations (859)
Job search strategy (127)
Layoffs (194)
Legal (1381)
Lung cancer (156)
Manufacturing (97)
Medical device (2567)
Medtech (2568)
Mergers & acquisitions (6189)
Metabolic disorders (300)
Neuroscience (1085)
NextGen: Class of 2025 (2013)
Non-profit (852)
Northern California (1253)
Obesity (163)
Opinion (95)
Parkinson's disease (88)
Patents (72)
People (25286)
Phase I (14278)
Phase II (18809)
Phase III (11888)
Pipeline (469)
Postmarket research (852)
Preclinical (5985)
Radiopharmaceuticals (208)
Rare diseases (236)
Real estate (1411)
Regulatory (8385)
Research institute (932)
Series A (75)
Southern California (1126)
Startups (1968)
United States (9959)
Vaccines (183)
Weight loss (94)
Date
Today (91)
Last 7 days (390)
Last 30 days (1704)
Last 365 days (20469)
2025 (1772)
2024 (20552)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23357)
2019 (16224)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (147)
Asia (17046)
Australia (2884)
California (2866)
Canada (910)
China (255)
Colorado (109)
Connecticut (118)
Europe (36672)
Florida (326)
Georgia (86)
Illinois (182)
Indiana (69)
Maryland (376)
Massachusetts (2278)
Minnesota (114)
New Jersey (715)
New York (788)
North Carolina (455)
Northern California (1253)
Ohio (93)
Pennsylvania (543)
South America (207)
Southern California (1126)
Texas (319)
Washington State (274)
263,596 Results for "palvella therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million
December 16, 2024
·
11 min read
Press Releases
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer
October 17, 2024
·
7 min read
Press Releases
Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations
January 9, 2025
·
7 min read
Press Releases
Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies
January 10, 2025
·
8 min read
Press Releases
Palvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference
October 15, 2024
·
8 min read
Press Releases
Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement
July 24, 2024
·
22 min read
Press Releases
Palvella Therapeutics Announces First Patient Dosed in SELVA Phase 3 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations
November 7, 2024
·
8 min read
Business
Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications
Palvella Therapeutics, Inc. today announced the expansion of their strategic partnership to accelerate Phase 3 development of QTORIN™ rapamycin for the treatment of Microcystic Lymphatic Malformations (Microcystic LMs).
December 1, 2023
·
4 min read
Press Releases
Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations
October 3, 2024
·
9 min read
FDA
Palvella Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations
Palvella Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations (Microcystic LMs).
November 16, 2023
·
4 min read
1 of 26,360
Next
